Neurogene Inc.
NGNE Healthcare Biotechnology
Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00. In the quarter to June 2026, EPS fell 45.7%, free cash flow fell 23.0% and total debt fell 66.7%, each against the same quarter a year earlier.
Follow NGNE
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
269.01 | 312.41 | 197.16 | 82.02 | 142.47 | 192.56 | 143.09 | 76.93 | 108.09 | 103.06 |
Receivables |
— | — | — | — | — | — | — | 0.24 | 0.74 | 0.43 |
Other current assets |
2.76 | 3.52 | 3.19 | 2.70 | 1.52 | 1.97 | 0.50 | 0.24 | 0.74 | 0.43 |
Total current assets |
271.77 | 315.92 | 200.35 | 84.72 | 143.99 | 194.52 | 143.60 | 77.17 | 108.83 | 103.49 |
Property, Plant, Equpment (Net) |
12.79 | 15.42 | 17.17 | 20.12 | 6.45 | 3.57 | 2.06 | 0.40 | 0.91 | 0.85 |
Long-Term Investments |
— | — | — | — | — | — | — | — | — | 50.05 |
Goodwill and Intangible Assets (Total) |
— | — | — | — | 0.13 | 0.35 | 0.57 | — | — | — |
Long-term assets (Other) |
1.37 | 1.31 | 1.27 | 0.94 | 1.93 | 1.93 | 0.03 | 0.05 | 0.60 | — |
Total non-current assets |
16.83 | 19.81 | 22.23 | 24.55 | 19.27 | 16.00 | 3.43 | 0.45 | 1.50 | 50.90 |
Total Assets |
288.60 | 335.73 | 222.57 | 109.27 | 163.26 | 210.52 | 147.02 | 77.62 | 110.33 | 154.38 |
Accounts Payable |
1.95 | 1.34 | 2.60 | 0.63 | 7.42 | 7.18 | 4.13 | 4.62 | 10.96 | 9.52 |
Accrued Expenses |
10.76 | 9.73 | 17.50 | 5.32 | — | — | — | — | — | — |
Current Part of Capital Lease |
0.01 | 0.05 | 0.04 | 0.02 | 0.06 | 0.05 | 0.06 | 0.01 | — | — |
Total current liabilities |
16.41 | 15.16 | 22.97 | 6.65 | 8.64 | 7.89 | 4.74 | 4.63 | 10.96 | 9.52 |
Long Term Debt (Total) |
0.01 | 0.03 | 0.07 | 0.07 | 0.07 | 0.11 | 0.15 | 0.01 | 0.03 | 0.05 |
Non-current Revenue (Deferred) |
— | — | — | — | — | — | — | 0.31 | 0.45 | 0.15 |
Non-current Liabilities (Other) |
0.05 | 0.05 | 0.20 | — | — | 0.00 | — | 0.32 | 0.49 | 0.20 |
Total non-current liabilities |
7.31 | 10.20 | 13.58 | 3.99 | 11.76 | 11.41 | 0.59 | 0.32 | 0.49 | 0.20 |
Total liabilities |
23.72 | 25.36 | 36.55 | 10.64 | 20.40 | 19.30 | 5.34 | 4.95 | 11.44 | 9.72 |
Additional Paid In Capital |
617.54 | 572.67 | 373.18 | 5.10 | 536.36 | 524.02 | 441.22 | 302.76 | 297.46 | 293.11 |
Preferred Stock (Total) |
— | — | — | 244.37 | — | — | — | — | — | — |
Retained Earnings |
(352.65) | (262.30) | (187.15) | (150.84) | (393.50) | (332.81) | (299.53) | (230.09) | (198.50) | (148.28) |
Common Equity (Total) |
264.89 | 310.38 | 186.02 | (145.74) | 142.86 | 191.22 | 141.69 | 72.67 | 98.89 | 144.66 |
Shareholders Equity (Total) |
264.89 | 310.38 | 186.02 | 98.63 | 142.86 | 191.22 | 141.69 | 72.67 | 98.89 | 144.66 |
Shareholders Equity and Liabilities (Total) |
288.60 | 335.73 | 222.57 | 109.27 | 163.26 | 210.52 | 147.02 | 77.62 | 110.33 | 154.38 |
Shares (Common) |
15.49 | 14.86 | 12.82 | 0.43 | 2.12 | 2.11 | 1.90 | 1.18 | 1.17 | 1.17 |
Shares (Preferred) |
— | — | — | 106.30 | — | — | — | — | — | — |
Shareholders Equity (Tangible) |
264.89 | 310.38 | 186.02 | 98.63 | 142.74 | 190.87 | 141.12 | 72.67 | 98.89 | 144.66 |
Net Debt |
(269.01) | (312.38) | (197.09) | (81.95) | (142.40) | (192.45) | (142.95) | (76.92) | (108.05) | (103.01) |
Total Debt |
0.01 | 0.03 | 0.07 | 0.07 | 0.07 | 0.11 | 0.15 | 0.01 | 0.03 | 0.05 |